货号:A129874
同义名:
PF-06687859; Quinazoline 495
RG3039 is an orally bioavailable and brain-penetrant DcpS inhibitor with IC50 of 0.069 nM.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | The human decapping scavenger enzyme (DcpS), belonging to the HIT family of pyrophosphatases, catalyzes residual cap hydrolysis following mRNA degradation and prevents accumulation of intermediates that might interfere with translation and normal processing of mRNAs[1]. RG3039 displays a potent DcpS inhibitory activity with an IC50 of 4.2 ± 0.13 nM and an IC90 of 40 nM in the DcpS inhibition assay. It shows good brain penetration with high brain-to-plasma partitioning and a half-life of ∼10 h. RG3039-treated (oral gavage with 20 mg/kg) SMA (spinal muscular atrophy) mice had a median survival that was 38% greater than vehicle-treated SMA mice[2]. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.31mL 0.46mL 0.23mL |
11.56mL 2.31mL 1.16mL |
23.13mL 4.63mL 2.31mL |
CAS号 | 1005504-62-0 |
分子式 | C21H23Cl2N5O |
分子量 | 432.35 |
SMILES Code | NC1=NC(N)=C2C(OCC3CCN(CC4=C(Cl)C=CC=C4Cl)CC3)=CC=CC2=N1 |
MDL No. | MFCD28716151 |
别名 | PF-06687859; Quinazoline 495; PF 6687859 |
运输 | 蓝冰 |
InChI Key | MNLHFGXIUJNDAF-UHFFFAOYSA-N |
Pubchem ID | 53258905 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Keep in dark place, sealed in dry, 2-8°C |